Radioisotope (RI) Synthesis for Radiolabeled Compound Studies in Drug Development
Radiolabeling is a very delicate science, almost an art, which requires precision, in-depth knowledge of studies in which the compound will be used, and experience with mistakes and common pitfalls in the synthesis process.
By choosing to work with an expert team with more than 50 years of radiolabeled compound synthesis and in vivo studies in pharmacokinetics and absorption, distribution, metabolism, and excretion (ADME), you can trust that your radioisotope (RI) work will be done with efficiency, saving you money and taking care of problem-solving you may otherwise have with a CRO of lesser experience.
Early-stage knowledge of the pharmacological effects of an investigational drug in the human body has become increasingly important to pursue during preclinical drug development in order to avoid costly late-stage clinical trial failures. For this reason, industry is more frequently conducting ADME studies in humans to better evaluate the performance of a drug early in the development pipeline (usually in Phase I).
In order to study a drug’s disposition, it is common to place a radioactive tag at a metabolically stable site on the investigational drug. Using the radioactive tag, we are able to identify any metabolites and detect structurally unidentified metabolites.
Performing radiolabeled synthesis at an early stage allows drug developers to make informed decisions about committing resources to the development of a chemical entity for commercial application, thereby reducing financial risk.
Our Approach to Radioisotope (RI) Synthesis
Each study contracted with us goes through a designated SEKISUI XenoTech study director to facilitate work with the Drug Development Solutions Center (DDSC) for in vivo and radiolabeling services. The DDSC has been accumulating experience in radiopharmaceutical production, custom synthesis of radiolabeled compounds, and in vivo ADME studies since 1965. Our RI compound synthesis service includes:
- Initial and ongoing consultation with expert radiochemists to determine synthetic route and yield at each step
- Synthesis guided by radioactivity required (mCi or MBq), isotope species, and specific activity (mCi/mmol)
- Careful, informed determination of labeling position
- Checks for chemical/radiochemical purity
- Certificate of Analysis issued for each compound synthesized in compliance with strict quality control
Radiolabeled Small Molecule / Protein / Peptide Capabilities
- 14C and 3H-labeled compound synthesis
- 3H, 33S, 35S, 90Y, 125I and 111In protein and peptide labeling
- Re-purification and stability test
- Storage / re-analysis
- Synthesis of biologically active substances
Access ADME is your portal to all of our scientific resources – check out all of our In Vivo/Radiolabeling related content, including information about regulatory expectations and expertise of the DDSC team in Tokai.